GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofil Chemicals & Pharmaceuticals Ltd (NSE:BIOFILCHEM) » Definitions » Capex-to-Revenue

Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Biofil Chemicals & Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Biofil Chemicals & Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹152.03 Mil.

Hence, Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Biofil Chemicals & Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofil Chemicals & Pharmaceuticals Capex-to-Revenue Chart

Biofil Chemicals & Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 - - -

Biofil Chemicals & Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue falls into.



Biofil Chemicals & Pharmaceuticals Capex-to-Revenue Calculation

Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.229) / 400.353
=0.00

Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 152.027
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofil Chemicals & Pharmaceuticals  (NSE:BIOFILCHEM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Biofil Chemicals & Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biofil Chemicals & Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Business Description

Traded in Other Exchanges
Address
11/12, Sector E, Sanwer Road, Industrial Area, Indore, MP, IND, 452015
Biofil Chemicals & Pharmaceuticals Ltd is an Indian-based pharmaceutical company. The company's operating segment includes Pharma and Chemicals. It generates maximum revenue from the Pharma segment.

Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Headlines

No Headlines